Company intelligence / Profile preview

Allarae HealthCare

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Allarae is a clinical-stage biotechnology company dedicated to developing transformative therapies for patients with severe food allergies and other immune-mediated conditions. The company's lead program, ALR-101, is a monoclonal antibody designed to provide rapid and sustained protection against allergic reactions by targeting IgE. Backed by leading life science investors like ARCH Venture Partners and GV, Allarae leverages deep expertise in immunology to create precision medicines. Their approach aims to significantly improve the safety and quality of life for individuals living with life-threatening allergies by providing a more convenient and effective therapeutic option than current treatments.

Therapeutic areas: Immunology
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Allarae HealthCare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allarae HealthCare.

Explore the full profile